Presentation is loading. Please wait.

Presentation is loading. Please wait.

NrasG12D induces CNS tumors in mice.

Published byKory Strickland Modified over 5 years ago

Similar presentations

Presentation on theme: "NrasG12D induces CNS tumors in mice."— Presentation transcript:

1 NrasG12D induces CNS tumors in mice.
NrasG12D induces CNS tumors in mice. A, Kaplan–Meier plot showing survival in months (mo) of study mice. The experimental groups consisted of Nras+/LSL-G12D;Tyr::CreA/° (+/G12D; n = 33) and NrasLSL-G12D/LSL-G12D; Tyr::CreA/° (G12D/G12D; n = 23) mice. The control groups consisted of Tyr::CreA/° (n = 22), Nras+/LSL-G12D (n = 13), and NrasLSL-G12D/LSL-G12D (n = 15)mice. B, photographs showing representative whole-brain and sagittal sections of the brains of control,Nras+/LSL-G12D;Tyr::CreA/° (+/G12D), and NrasLSL-G12D/LSL-G12D;Tyr::CreA/° (G12D/G12D) mice. C, photomicrograph of an H&E-stained brain section from an NrasLSL-G12D/LSL-G12D;Tyr::CreA/° mouse (boxed area in the bottom image of B), displaying proliferation of pigmented melanocytes in the leptomeninges along the external surface of the brain parenchyma (black arrow). Scale bar, 100 μm. D, photomicrograph of an H&E-stained frontal lobe melanoma from an NrasLSL-G12D/LSL-G12D;Tyr::CreA/° mouse, showing leptomeningeal spread of melanoma cells (black arrows). Scale bar, 1 mm. E, photomicrograph showing nuclear Ki67 staining (white arrows) of a representative melanoma from an NrasLSL-G12D/LSL-G12D;Tyr::CreA/° mouse. Note that some cells are melanin laden (black arrowheads). Scale bar, 20 μm. L, D. leptomeninges; P, brain parenchyma. F, high-power photomicrograph of boxed area in D of an H&E-stained melanoma with atypical, epithelioid cells. Tumor cells frequently presented intracytoplasmic melanin (black arrowheads). Scale bar, 25 μm. G, photomicrograph showing HMB45/MelanA staining in a representative melanoma from an NrasLSL-G12D/LSL-G12D;Tyr::CreA/° mouse. Note the predominant membranous staining and presence of intracytoplasmic deposits of melanin in the melanoma cells (black arrowheads). Scale bar, 50 μm. H, Western blot analysis of ppERK and total ERK levels of Nras-mutant melanoma cells following MEK inhibition for 3 hours using PD184352, U0126, and AZD6244. I, in vivo allograft experiment, using Nras-mutant cells from a mouse brain melanoma showing the effect of the MEK inhibitor PD on intradermal tumor growth in C57Bl/6 mice (n = 6 PD treated mice and 9 vehicle-treated mice). Malin Pedersen et al. Cancer Discovery 2013;3: ©2013 by American Association for Cancer Research

Download ppt "NrasG12D induces CNS tumors in mice."

Similar presentations

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.
Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.

Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.
Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.
MAPK pathway inhibitors.

MAPK pathway inhibitors.
Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.
Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.
18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.

18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.
25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.

25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.
Intracranial Tumor Cell Migration and the Development of Multiple Brain Metastases in Malignant Melanoma  Trude G. Simonsen, Jon-Vidar Gaustad, Einar.

Intracranial Tumor Cell Migration and the Development of Multiple Brain Metastases in Malignant Melanoma  Trude G. Simonsen, Jon-Vidar Gaustad, Einar.
Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.
Effects of SC144 on in vivo ovarian tumor.

Effects of SC144 on in vivo ovarian tumor.
Acute, systemic Atg7 deficiency compromises tumorigenesis.

Acute, systemic Atg7 deficiency compromises tumorigenesis.
DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.

DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.
Deficiency of Cdkn2a leads to aberrant activation of RhoA in vivo.

Deficiency of Cdkn2a leads to aberrant activation of RhoA in vivo.
The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.

The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.
Merlin-deficient RAS-mutant cells and murine PDTCs are more sensitive to MEK inhibition. Merlin-deficient RAS-mutant cells and murine PDTCs are more sensitive.

Merlin-deficient RAS-mutant cells and murine PDTCs are more sensitive to MEK inhibition. Merlin-deficient RAS-mutant cells and murine PDTCs are more sensitive.
Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.
Einar K. Rofstad, Bjørn A. Graff  Journal of Investigative Dermatology 

Einar K. Rofstad, Bjørn A. Graff  Journal of Investigative Dermatology 
Animal Models of Melanoma

Animal Models of Melanoma
Volume 20, Issue 6, Pages (December 2011)

Volume 20, Issue 6, Pages (December 2011)

Similar presentations

Ads by Google